<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-MJCRWDDF</identifier><date>2018</date><creator>Mencinger, Marina</creator><relation>documents/doc/M/URN_NBN_SI_doc-MJCRWDDF_001.pdf</relation><relation>documents/doc/M/URN_NBN_SI_doc-MJCRWDDF_001.txt</relation><format format_type="issue">1</format><format format_type="volume">22</format><format format_type="type">article</format><format format_type="extent">str. 24-27</format><identifier identifier_type="ISSN">1408-1741</identifier><identifier identifier_type="COBISSID_HOST">2990971</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-MJCRWDDF</identifier><language>slv</language><publisher>Onkološki inštitut Ljubljana</publisher><source>Onkologija (Ljubljana)</source><rights>BY</rights><subject language_type_id="eng">side effects</subject><subject language_type_id="slv">stranski učinki</subject><subject language_type_id="slv">tarčna zdravila</subject><subject language_type_id="eng">targeted drugs</subject><subject language_type_id="eng">tyrosine kinase inhibitors</subject><subject language_type_id="slv">zaviralci tirozinskih kinaz</subject><title>Side effects of tyrosine kinase inhibitors in cancer treatment</title><title>Stranski učinki ob zdravljenju rakavih bolezni z zaviralci tirozinskih kinaz</title></Record>